EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy

Eeva Feuth, Valtteri Nieminen, Antti Palomäki, Juha Ranti, Marcus Sucksdorff, Taru Finnilä, Jarmo Oksi, Tytti Vuorinen, Thijs Feuth

European Journal of Clinical Microbiology & Infectious Diseases · 2024-04 · 43 (4) · 723-734

DOI: 10.1007/s10096-024-04776-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 15.02.2024. Verfasst von Eeva Feuth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Turku University Hospital and University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: COVID-19, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In clinical practice, we observed an apparent overrepresentation of COVID-19 patients on anti-CD20 monoclonal antibody therapy. The aim of this study was to characterize the clinical picture of COVID-19 in these patients.

Methods

All adult patients from Turku University Hospital, Turku, Finland, with COVID-19 diagnosis and/or positive SARS-CoV-2 PCR test result up to March 2023, and with anti-CD20 therapy within 12 months before COVID-19 were included. Data was retrospectively obtained from electronic patient records.

Results

Ninety-eight patients were identified. 44/93 patients (47.3%) were hospitalized due to COVID-19. Patients with demyelinating disorder ( n = 20) were youngest (median age 36.5 years, interquartile range 33–45 years), had less comorbidities, and were least likely to be hospitalized (2/20; 10.0%) or die ( n = 0). COVID-19 mortality was 13.3% in the whole group, with age and male sex as independent risk factors. Persistent symptoms were documented in 33/94 patients (35.1%) alive by day 30, in 21/89 patients (23.6%) after 60 days, and in 15/85 after 90 days (17.6%), mostly in patients with haematological malignancy or connective tissue disease. Prolonged symptoms after 60 days predisposed to persistent radiological findings (odds ratio 64.0; 95% confidence interval 6.3–711; p < 0.0001) and persistently positive PCR (odds ratio 45.5, 95% confidence interval 4.0–535; p < 0.0001). Several patients displayed rapid response to late antiviral therapy.

Conclusion

Anti-CD20 monoclonal antibody therapy is associated with high COVID-19 mortality and with a phenotype consistent with prolonged viral pneumonia. Our study provides rationale for retesting of immunocompromised patients with prolonged COVID-19 symptoms and considering antiviral therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antineoplastic AgentsAdultHumansMaleMiddle AgedSARS-CoV-2COVID-19 TestingRetrospective StudiesAntibodies, MonoclonalAntiviral Agents

Stichwörter der Autor:innen

Anti-CD20 mAbCOVID-19ImmunosuppressionRituximabSARS-CoV-2Viral pneumonia

Substanzen

Antineoplastic AgentsAntibodies, MonoclonalAntiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Turku University Hospital and University of Turku, Turku, Finland.
  • Department of Pulmonary Diseases and Clinical Allergology, Turku University Hospital and University of Turku, Turku, Finland.
  • Centre for Rheumatology and Clinical Immunology, and Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Department of Haematology, Turku University Hospital, Turku, Finland.
  • Turku PET Centre, and Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland.
  • Department of Hospital Hygiene & Infection Control, Turku University Hospital, Turku, Finland.

Förderung

  • University of Turku

Zitieren

APA

Feuth, E., Nieminen, V., Palomäki, A., Ranti, J., Sucksdorff, M., Finnilä, T., Oksi, J., Vuorinen, T., & Feuth, T. (2024). Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy. European Journal of Clinical Microbiology & Infectious Diseases, 43(4), 723-734. https://doi.org/10.1007/s10096-024-04776-0

Vancouver

Feuth E, Nieminen V, Palomäki A, Ranti J, Sucksdorff M, Finnilä T, et al. Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy. European Journal of Clinical Microbiology & Infectious Diseases. 2024;43(4):723-734. doi:10.1007/s10096-024-04776-0

BibTeX
@article{Feuth2024,
  author = {Feuth, Eeva and Nieminen, Valtteri and Palomäki, Antti and Ranti, Juha and Sucksdorff, Marcus and Finnilä, Taru and Oksi, Jarmo and Vuorinen, Tytti and Feuth, Thijs},
  title = {Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  volume = {43},
  number = {4},
  pages = {723--734},
  doi = {10.1007/s10096-024-04776-0}
}
Kostenlos starten →